Abstract 2760
Background
TMB is an emerging biomarker for immune-therapy including metastasized UBC. The evaluation of reliable methods to determine the TMB value is a prerequisite for successful application of IO therapies.
Methods
TMB was assessed in genomic DNA from 39 muscle-invasive UBC by whole genome sequencing (GPS Cancer©, NantHealth). In 45 cases sequencing with the TruSight Oncology 500, (TSO500, Illumina) was performed. Immune cell (IC) infiltrates were analyzed by CD3, CD8, CD56, PD-1 and CD68 immunohistochemistry. PD-L1 status was evaluated by the SP263 assay (Ventana). Intrinsic subtypes (MDACC-approach) were assessed via a Nanostring-assay. Immune phenotypes were assessed by (I) spatial distribution of IC and (II) a T-cell inflammation related gene expression signature consisting of 29 genes (Nanostring). Results were validated in the TCGA MIBC cohort.
Results
Correlation between TSO500 and WGS revealed high concordance (spearman-correlation: r = 0.68, p < 0.0001). Overall percentage agreement was 76.9% for a cut-off of 10 mut/mb and 84.6% for 15 mut/mb. We found no significant association of high TMB at different cut-offs (10 mut/mb, 15 mut/mb) with inflammation status and different immune cell populations in both cohorts. TMB was not associated with intrinsic subtypes. Spatially distributed IC phenotypes or PD-L1 status was not associated with TMB. Hierarchical clustering of all factors revealed four distinct subgroups: Cluster A Inflamed, PD-L1 “high”, TMB high (n = 5); Cluster B Inflamed, PD-L1 “high”, TMB low-intermediate (n = 14); Cluster C: Uninflamed, PD-L1 “low”, TMB intermediate-high (n = 14); Cluster D Uninflamed, PD-L1 “low”, TMB low (n = 12).
Conclusions
This study provides insights into the reliability of a NGS panel for the prediction of TMB in MIBC which shows comparable performance to WGS. High TMB seems to be a characteristic of MIBC which occurs regardless of PD-L1 and inflammation status. TMB could possibly identify additional patients who do not fulfill the PD-L1 assessment based criteria for checkpoint inhibition.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Illumina, California, United States of America NantHealth, Culver City, California, United States of America.
Disclosure
M. Eckstein: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Janssen-Cilag. All other authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract